Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you considering substituting infusional 5FU for capecitabine in the FLOT regimen for localized gastric adenocarcinoma?
Answer from: Medical Oncologist at Academic Institution
No. I'm not aware of any high-quality data for such a regimen.
Sign in or Register to read more
3092
Related Questions
What are your top takeaways in GI Cancers from ESMO 2024?
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
Is there data to support the upfront use of encorafenib and cetuximab in metastatic BRAF V600E-mutated right-sided colon cancer?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
What systemic therapy (FOLFOX or mFOLFIRINOX) would you use in T3 N1 M1 MMR proficient rectal cancer with solitary liver lesion when going for curative intent ( chemo --> short course RT --> resection of primary and liver met)?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
For patients with large, partially or nearly obstructing rectal cancers, how do you sequence TNT in order to avoid complete obstruction and surgical diversion?
What is the role of checkpoint inhibitor doublet such as ipilimumab and nivolumab in patients with MSI-high metastatic colon cancer and lynch syndrome who progressed through prior pembrolizumab and subsequent chemotherapy?